<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Can J Kidney Health Dis</journal-id><journal-id journal-id-type="iso-abbrev">Can J Kidney Health Dis</journal-id><journal-title-group><journal-title>Canadian Journal of Kidney Health and Disease</journal-title></journal-title-group><issn pub-type="epub">2054-3581</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26284153</article-id><article-id pub-id-type="pmc">4538753</article-id><article-id pub-id-type="publisher-id">66</article-id><article-id pub-id-type="doi">10.1186/s40697-015-0066-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Badve</surname><given-names>Sunil V.</given-names></name><address><phone>+61 7 3176 5080</phone><email>s.badve@uq.edu.au</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lei</given-names></name><address><email>l.zhang13@uq.edu.au</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Coombes</surname><given-names>Jeff S.</given-names></name><address><email>jcoombes@uq.edu.au</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Pascoe</surname><given-names>Elaine M.</given-names></name><address><email>e.pascoe@uq.edu.au</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Cass</surname><given-names>Alan</given-names></name><address><email>Alan.Cass@menzies.edu.au</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Clarke</surname><given-names>Philip</given-names></name><address><email>philip.clarke@unimelb.edu.au</email></address><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Ferrari</surname><given-names>Paolo</given-names></name><address><email>Paolo.Ferrari@SESIAHS.HEALTH.NSW.GOV.AU</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>McDonald</surname><given-names>Stephen P.</given-names></name><address><email>Stephen@anzdata.org.au</email></address><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Morrish</surname><given-names>Alicia T.</given-names></name><address><email>a.morrish@uq.edu.au</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Pedagogos</surname><given-names>Eugenie</given-names></name><address><email>Eugenie.Pedagogos@mh.org.au</email></address><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author"><name><surname>Perkovic</surname><given-names>Vlado</given-names></name><address><email>VPerkovic@georgeinstitute.org.au</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Reidlinger</surname><given-names>Donna</given-names></name><address><email>d.reidlinger@uq.edu.au</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Scaria</surname><given-names>Anish</given-names></name><address><email>a.scaria@uq.edu.au</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Walker</surname><given-names>Rowan</given-names></name><address><email>R.Walker@alfred.org.au</email></address><xref ref-type="aff" rid="Aff11"/></contrib><contrib contrib-type="author"><name><surname>Vergara</surname><given-names>Liza A.</given-names></name><address><email>l.vergara@uq.edu.au</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Hawley</surname><given-names>Carmel M.</given-names></name><address><email>Carmel.Hawley@health.qld.gov.au</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>David W.</given-names></name><address><email>David.Johnson2@health.qld.gov.au</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><collab>on behalf of the HERO Study Collaborative Group</collab></contrib><aff id="Aff1"><label/>Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia </aff><aff id="Aff2"><label/>Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia </aff><aff id="Aff3"><label/>Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China </aff><aff id="Aff4"><label/>School of Human Movement Studies, University of Queensland, Brisbane, Australia </aff><aff id="Aff5"><label/>Menzies School of Health Research, Darwin, Australia </aff><aff id="Aff6"><label/>Centre for Health Policy, Programs &#x00026; Economics, University of Melbourne, Melbourne, Australia </aff><aff id="Aff7"><label/>Department of Nephrology, Prince of Wales Hospital, Sydney, Australia </aff><aff id="Aff8"><label/>Department of Nephrology and Transplantation Services, University of Adelaide at Central Northern Adelaide Renal and Transplantation Services, Adelaide, Australia </aff><aff id="Aff9"><label/>Department of Nephrology, Royal Melbourne Hospital, Melbourne, Australia </aff><aff id="Aff10"><label/>The George Institute for Global Health, Sydney, Australia </aff><aff id="Aff11"><label/>Department of Renal Medicine, The Alfred Hospital, Melbourne, Australia </aff><aff id="Aff12"><label/>Department of Nephrology, Level 2, ARTS Building, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Queensland 4102 Australia </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>2</volume><elocation-id>33</elocation-id><history><date date-type="received"><day>17</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>29</day><month>7</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Badve et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Erythropoiesis stimulating agent (ESA)-resistant anemia is common in chronic kidney disease (CKD).</p></sec><sec><title>Objectives</title><p>To evaluate the determinants of severity of ESA resistance in patients with CKD and primary ESA-resistance.</p></sec><sec><title>Design</title><p>Secondary analysis of a randomized controlled trial (the Handling Erythropoietin Resistance with Oxpentifylline, HERO)</p></sec><sec><title>Setting and patients</title><p>53 adult patients with CKD stage 4 or 5 and primary ESA-resistant anemia (hemoglobin &#x02264;120&#x000a0;g/L, ESA resistance index [ERI] &#x02265;1.0&#x000a0;IU/kg/week/gHb for erythropoietin or &#x02265;0.005&#x000a0;&#x003bc;g/kg/week/gHb for darbepoeitin, no cause for ESA-resistance identified).</p></sec><sec><title>Measurements</title><p>Iron studies, parathyroid hormone, albumin, liver enzymes, phosphate or markers of oxidative stress and inflammation.</p></sec><sec><title>Methods</title><p>Participants were divided into tertiles of ERI. Multinomial logistic regression was used to analyse the determinants of ERI tertiles.</p></sec><sec><title>Results</title><p>All patients, except one, were receiving dialysis for end-stage kidney disease. The mean&#x02009;&#x000b1;&#x02009;SD ERI values in the low (<italic>n</italic>&#x02009;=&#x02009;18), medium (<italic>n</italic>&#x02009;=&#x02009;18) and high (<italic>n</italic>&#x02009;=&#x02009;17) ERI tertiles were 1.4&#x02009;&#x000b1;&#x02009;0.3, 2.3&#x02009;&#x000b1;&#x02009;0.2 and 3.5&#x02009;&#x000b1;&#x02009;0.8&#x000a0;IU/kg/week/gHb, respectively (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). There were no significant differences observed in age, gender, ethnicity, cause of kidney disease, diabetes, iron studies, parathyroid hormone, albumin, liver enzymes, phosphate or markers of oxidative stress and inflammation between the ERI tertiles. The median [inter-quartile range] serum alkaline phosphatase concentrations in the low, medium and high ERI tertiles were 89 [64,121], 99 [76,134 and 148 [87,175] U/L, respectively (<italic>P</italic>&#x02009;=&#x02009;0.054). There was a weak but statistically significant association between ERI and serum alkaline phosphatase (R<sup>2</sup>&#x02009;=&#x02009;0.06, <italic>P</italic>&#x02009;=&#x02009;0.03). Using multinomial logistic regression, the risk of being in the high ERI tertile relative to the low ERI tertile increased with increasing serum alkaline phosphatase levels (<italic>P</italic>&#x02009;=&#x02009;0.02). No other variables were significantly associated with ERI.</p></sec><sec><title>Limitations</title><p>Small sample size; bone-specific alkaline phosphatase, other markers of bone turnover and bone biopsies not evaluated.</p></sec><sec><title>Conclusions</title><p>Serum alkaline phosphatase was associated with severity of ESA resistance in ESA-resistant patients with CKD. Large prospective studies are required to confirm this association. (Trial registration: Australian New Zealand Clinical Trials Registry 12608000199314)</p></sec></abstract><trans-abstract xml:lang="fr" id="Abs2"><title>R&#x000e9;sum&#x000e9;</title><sec><title>Contexte</title><p>L&#x02019;an&#x000e9;mie r&#x000e9;sistante &#x000e0; l&#x02019;agent stimulant l&#x02019;&#x000e9;rythropo&#x000ef;&#x000e8;se (ASE) est courante chez les patients atteints d&#x02019;insuffisance r&#x000e9;nale chronique (IRC).</p></sec><sec><title>Objectifs</title><p>&#x000c9;valuer les d&#x000e9;terminants de la gravit&#x000e9; de la r&#x000e9;sistance &#x000e0; l&#x02019;ASE chez les patients atteints d&#x02019;IRC et de la r&#x000e9;sistance primaire &#x000e0; l&#x02019;ASE.</p></sec><sec><title>Type d&#x02019;&#x000e9;tude</title><p>Analyse secondaire d&#x02019;un essai clinique randomis&#x000e9; (le Handling Erythropoietin Resistance with Oxpentifylline, HERO)</p></sec><sec><title>Contexte et participants</title><p>53 patients adultes atteints d&#x02019;IRC de stade 4 ou 5, de m&#x000ea;me que d&#x02019;an&#x000e9;mie r&#x000e9;sistante &#x000e0; l&#x02019;ASE (h&#x000e9;moglobine &#x02264;120&#x000a0;g/L, indice de r&#x000e9;sistance &#x000e0; l&#x02019;ASE [IRA] &#x02265;1,0&#x000a0;IU/kg/semaine/gHb pour l&#x02019;&#x000e9;rythropo&#x000ef;&#x000e9;tine ou &#x02265;0,005&#x000a0;&#x003bc;g/kg/semaine/gHb pour la darb&#x000e9;po&#x000e9;tine, aucune cause justifiant la r&#x000e9;sistance &#x000e0; l&#x02019;ASE).</p></sec><sec><title>Mesures</title><p>Mesure des taux de fer, de la parathormone, de l&#x02019;albumine, de l&#x02019;enzyme h&#x000e9;patique, du phosphate ou des marqueurs de stress oxydatif et d&#x02019;inflammation.</p></sec><sec><title>M&#x000e9;thodes</title><p>Les participants &#x000e9;taient divis&#x000e9;s en tertiels d&#x02019;IRA. La m&#x000e9;thode de r&#x000e9;gression logistique multinominale a &#x000e9;t&#x000e9; utilis&#x000e9;e pour analyser les d&#x000e9;terminants des tertiels d&#x02019;IRA.</p></sec><sec><title>R&#x000e9;sultats</title><p>Tous les patients, sauf un, recevaient une dialyse pour l&#x02019;IRT. La moyenne&#x02009;&#x000b1;&#x02009;&#x000c9;T des valeurs d&#x02019;IRA des tertiels inf&#x000e9;rieur (<italic>n</italic>&#x02009;=&#x02009;18), interm&#x000e9;diaire (<italic>n</italic>&#x02009;=&#x02009;18) et sup&#x000e9;rieur (<italic>n</italic>&#x02009;=&#x02009;17) &#x000e9;taient respectivement de 1,4&#x02009;&#x000b1;&#x02009;0,3, de 2,3&#x02009;&#x000b1;&#x02009;0,2 et de 3,5&#x02009;&#x000b1;&#x02009;0,8&#x000a0;IU/kg/semaine/gHb (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0,001). On n&#x02019;a observ&#x000e9; aucune diff&#x000e9;rence importante en fonction de l&#x02019;&#x000e2;ge, du sexe, de l&#x02019;ethnicit&#x000e9;, de la cause de l&#x02019;insuffisance r&#x000e9;nale, du diab&#x000e8;te, des taux de fer, de la parathormone, de l&#x02019;albumine, de l&#x02019;enzyme h&#x000e9;patique, du phosphate ou des marqueurs de stress oxydatif et d&#x02019;inflammation entre les tertiels d&#x02019;IRA. La m&#x000e9;diane [&#x000e9;cart interquartile] des concentrations de phosphatase alcaline s&#x000e9;rique des tertiels d&#x02019;IRA inf&#x000e9;rieur, interm&#x000e9;diaire et sup&#x000e9;rieur &#x000e9;taient respectivement de 89 [64,121], de 99 [76,134] et de 148 [87,175] U/L (<italic>P</italic>&#x02009;=&#x02009;0,054). Bien que statistiquement significative, la relation &#x000e9;tait plut&#x000f4;t faible entre l&#x02019;IRA et la phosphatase alcaline s&#x000e9;rique (R<sup>2</sup>&#x02009;=&#x02009;0,06; <italic>P</italic>&#x02009;=&#x02009;0,03). Selon la m&#x000e9;thode de r&#x000e9;gression logistique multinominale, les chances de se retrouver dans le tertiel d&#x02019;IRA sup&#x000e9;rieur, par opposition au tertiel d&#x02019;IRA inf&#x000e9;rieur, augmentait avec des taux &#x000e9;lev&#x000e9;s de phosphatase alcaline s&#x000e9;rique (P&#x02009;=&#x02009;0,02). On n&#x02019;a observ&#x000e9; aucune association forte entre une autre variable et l&#x02019;IRA.</p></sec><sec><title>Conclusion</title><p>La phosphatase alcaline s&#x000e9;rique a &#x000e9;t&#x000e9; associ&#x000e9;e &#x000e0; une forte r&#x000e9;sistance &#x000e0; l&#x02019;ASE chez les patients r&#x000e9;sistants &#x000e0; l&#x02019;ASE atteints d&#x02019;IRC. Des &#x000e9;tudes prospectives &#x000e0; grande &#x000e9;chelle sont n&#x000e9;cessaires afin de confirmer cette association. (Enregistrement de l&#x02019;essai clinique: Australian New Zealand Clinical Trials Registry 12608000199314)</p></sec></trans-abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Erythropoiesis stimulating agents</kwd><kwd>Anemia</kwd><kwd>Chronic kidney disease</kwd><kwd>Alkaline phosphatase</kwd><kwd>Biological marker</kwd><kwd>Risk factors</kwd><kwd>Randomized controlled trial</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Short section</title><sec id="Sec2"><title>What was known before</title><p>Increased serum alkaline phosphatase is associated with decreased responsiveness to erythropoiesis stimulating agents in patients with end-stage kidney disease.</p></sec><sec id="Sec3"><title>What this study adds</title><p>Serum alkaline phosphatase is associated with severity of resistance to erythropoiesis stimulating agents in patients with chronic kidney disease with no identifiable causes for resistance to erythropoiesis stimulating agents.</p></sec></sec><sec id="Sec4" sec-type="introduction"><title>Background</title><p>Since the introduction of erythropoiesis stimulating agents (ESA), there have been substantial reductions in the blood transfusion requirements of patients suffering from chronic kidney disease (CKD) [<xref ref-type="bibr" rid="CR1">1</xref>]. Unfortunately, 7&#x02013;14&#x000a0;% of all patients with end-stage kidney disease (ESKD) show a suboptimal hematologic response to ESA (Hb concentration &#x0003c;100&#x000a0;g/L) [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. There are several known causes of suboptimal response to ESA. These include: female gender; [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>] old age; [<xref ref-type="bibr" rid="CR7">7</xref>] diabetes mellitus; [<xref ref-type="bibr" rid="CR9">9</xref>] cardiovascular disease; [<xref ref-type="bibr" rid="CR5">5</xref>] lower body mass index; [<xref ref-type="bibr" rid="CR10">10</xref>] malnutrition; [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>] inflammation; [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>] deficiencies of iron, [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>] vitamin B12, [<xref ref-type="bibr" rid="CR16">16</xref>] folate [<xref ref-type="bibr" rid="CR17">17</xref>] or vitamin D; [<xref ref-type="bibr" rid="CR18">18</xref>] hyperphosphatemia; [<xref ref-type="bibr" rid="CR19">19</xref>] hyperparathyroidism; [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>] elevated levels of serum alkaline phosphatase; [<xref ref-type="bibr" rid="CR15">15</xref>] inadequate dialysis; [<xref ref-type="bibr" rid="CR8">8</xref>] infection; [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>] malignancy; [<xref ref-type="bibr" rid="CR7">7</xref>] use of ACE inhibitors or angiotensin receptor blockers; [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] presence of a failed kidney transplant; [<xref ref-type="bibr" rid="CR23">23</xref>] and anti-erythropoietin antibodies [<xref ref-type="bibr" rid="CR24">24</xref>]. However, after excluding these conditions, a significant proportion of patients exhibit primary ESA-resistant anemia. The incidence and factors responsible for <italic>primary</italic> resistance to ESA are unknown.</p><p>ESA treatment targeting hemoglobin levels above 130&#x000a0;g/L in people with CKD is associated with deleterious [<xref ref-type="bibr" rid="CR25">25</xref>] or neutral [<xref ref-type="bibr" rid="CR26">26</xref>] impacts on survival and increased risks of stroke, vascular access thrombosis and hypertension without any reduction in cardiovascular events [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. However, recently published studies have demonstrated that poor response to ESA treatment, rather than achieved high hemoglobin, is associated with the observed adverse outcomes in CKD [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. Unfortunately, there are no established therapies for primary ESA-resistant anemia [<xref ref-type="bibr" rid="CR31">31</xref>]. The Handling Erythropoietin Resistance with Oxpentifylline (HERO) trial evaluated the effect of pentoxifylline on erythropoiesis resistance index (ERI) in patients with advanced CKD and primary ESA-hyporesponsive anemia [<xref ref-type="bibr" rid="CR32">32</xref>]. We conducted a post-hoc analysis of the HERO Study to evaluate the determinants of severity of ESA resistance.</p></sec><sec id="Sec5" sec-type="materials|methods"><title>Methods</title><p>Details of the HERO Study protocol and population are described elsewhere [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. In brief, the HERO Study (registration number Australian New Zealand Clinical Trials Registry 12608000199314) was a multi-centre, double-blind, randomized placebo-controlled trial to study the effect of pentoxifylline on ERI. The study was approved by ethics committees at all participating centres. All patients provided written informed consent prior to trial participation and the trial was conducted in accordance with the principles of the International Conference on Harmonisation Good Clinical Practice Guideline.</p><p>Between June 2009 and December 2011, the study enrolled 53 adult patients with stages 4 or 5 CKD (receiving dialysis treatment or estimated GFR &#x0003c;30&#x000a0;ml/min/1.73&#x000a0;m<sup>2</sup>) and ESA- resistant anemia on a stable dose of either erythropoietin or darbepoetin for at least 8&#x000a0;weeks. ESA-resistant anemia was defined as hemoglobin concentration &#x02264;120&#x000a0;g/L and ERI &#x02265;1.0&#x000a0;IU/kg/week per g/L for erythropoietin and &#x02265;0.005&#x000a0;&#x003bc;g/kg/week per g/L for darbepoetin. ERI was calculated as weight-adjusted weekly dose of ESA divided by hemoglobin concentration, (expressed as IU/kg/week per g/L). ERI for darbepoetin-treated patients was converted to an erythropoietin-equivalent value using a dose conversion factor of 200:1.</p><p>Patients with an identifiable cause for their ESA hyporesponsiveness (such as iron deficiency, bleeding, inadequate dialysis, parathyroid hormone &#x0003e;100 pmol/L, malignancy or hematologic disorder, major surgery, infection, acute myocardial infarction or malignancy within the last 3&#x000a0;months) were excluded. Participants were randomized in a 1:1 ratio to receive pentoxifylline (Trental&#x000ae;, Sanofi-Aventis, Sydney, Australia) 400&#x000a0;mg daily orally or an identical matching placebo. The randomization was performed by an adaptive allocation algorithm designed to minimize imbalance in treatment groups across three variables: study site; CKD stage (4 or 5) and ESA class (erythropoietin or darbepoetin) using a password-protected web-based system. The follow up period was 4&#x000a0;months, unless a participant experienced a hemoglobin concentration &#x0003c;65&#x000a0;g/L or required a blood transfusion. The primary efficacy outcome was ERI. Secondary outcome variables were hemoglobin concentration, ESA dose, rate of blood transfusions, adverse events, quality of life and cost-effectiveness analysis. Of the 53 participants, plasma samples for four oxidative stress biomarkers (total F2-isoprostanes, protein carbonyls, glutathione peroxidase [GPX] and superoxide dismutase [SOD] activities) were available in 41 participants.</p><sec id="Sec6"><title>Statistical analysis</title><p>This post-hoc analysis included only the baseline data from the main HERO Study and oxidative stress substudy. Results were expressed as frequencies (percentages) for categorical variables, mean&#x02009;&#x000b1;&#x02009;standard deviation for continuous normally distributed variables and median [interquartile range] for continuous non-normally distributed variables. Participants were divided into tertiles of ERI (low, medium and high ERI). Differences between groups of patients were analysed by <italic>&#x003c7;</italic><sup>2</sup> test for categorical data; one-way analysis of variance for continuous variables if data were normally distributed and Kruskal&#x02013;Wallis test for non-normally distributed data. Simple linear regression was used to analyze the association between ERI and other variables. Non-normally distributed variables were appropriately transformed to improve normality of distribution. Associations between ERI and the following variables were analysed in linear regression models: gender, ethnicity, diabetes mellitus, cause of kidney disease, smoking status, ischemic heart disease, congestive heart failure, and body mass index category, age, reticulocyte count, total white cell count, ferritin, transferrin saturation, albumin, alkaline phosphatase, gamma-glutamyltransferase, alanine transaminase, aspartate transaminase, lactate dehydrogenase, albumin-corrected calcium, phosphate, parathyroid hormone, C-reactive protein, total F2-isoprostanes, protein carbonyls, GPX and SOD activities. Predictors of high ERI tertile versus low and medium ERI tertiles were determined by univariate multinomial logistic regression models. The same above mentioned variables were used in these models. Analysis was conducted using Stata/SE (version 11.2, Stata Corp., College Station, TX, USA).</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><sec id="Sec8"><title>Patient characteristics</title><p>Baseline characteristics of the study population according to ERI tertiles are described in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The mean ERI values in the low, medium and high ERI tertiles were 1.4&#x02009;&#x000b1;&#x02009;0.3, 2.3&#x02009;&#x000b1;&#x02009;0.2 and 3.5&#x02009;&#x000b1;&#x02009;0.8&#x000a0;IU/kg/week/gHb, respectively. Increasing ERI was associated with both higher ESA dose and lower hemoglobin level (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Serum alkaline phosphatase concentrations also increased with increasing ERI. Median [IQR] serum alkaline phosphatase levels in the low, medium and high ERI tertiles were 89 [64, 121], 99 [76, 134] and 148 [87, 175] U/L, respectively (<italic>P</italic>&#x02009;=&#x02009;0.054, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). There were no statistically significant differences observed between the ERI tertiles with respect to age, gender, ethnic origin, cause of kidney disease, smoking status, dialysis modality, comorbidities, body mass index, other laboratory values or oxidative stress markers (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics according to tertiles of ERI</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th colspan="3">ERI tertile</th><th rowspan="2">
<italic>P</italic>
</th></tr><tr><th>Low</th><th>Medium</th><th>High</th></tr></thead><tbody><tr><td>n</td><td>18</td><td>18</td><td>17</td><td/></tr><tr><td>ERI (IU/kg/wk/gHb)</td><td>1.4&#x02009;&#x000b1;&#x02009;0.3</td><td>2.3&#x02009;&#x000b1;&#x02009;0.2</td><td>3.5&#x02009;&#x000b1;&#x02009;0.8</td><td>&#x0003c;0.001</td></tr><tr><td>ESA dose (IU/kg/wk)<sup>a</sup>
</td><td>153&#x02009;&#x000b1;&#x02009;37</td><td>233&#x02009;&#x000b1;&#x02009;25</td><td>362&#x02009;&#x000b1;&#x02009;79</td><td>&#x0003c;0.001</td></tr><tr><td>
<italic>Type of ESA</italic>
</td><td/><td/><td/><td>0.8</td></tr><tr><td>Erythropoietin</td><td>11 (61&#x000a0;%)</td><td>12 (67&#x000a0;%)</td><td>12 (71&#x000a0;%)</td><td/></tr><tr><td>Darbepoetin</td><td>7 (39&#x000a0;%)</td><td>6 (33&#x000a0;%)</td><td>5 (29&#x000a0;%)</td><td/></tr><tr><td>Hemoglobin (g/L)</td><td>111&#x02009;&#x000b1;&#x02009;8</td><td>102&#x02009;&#x000b1;&#x02009;13</td><td>105&#x02009;&#x000b1;&#x02009;10</td><td>0.05</td></tr><tr><td>Men</td><td>10 (56&#x000a0;%)</td><td>8 (44&#x000a0;%)</td><td>6 (35&#x000a0;%)</td><td>0.5</td></tr><tr><td>Age (years)</td><td>67.7&#x02009;&#x000b1;&#x02009;13</td><td>58.4&#x02009;&#x000b1;&#x02009;17.6</td><td>60.5&#x02009;&#x000b1;&#x02009;15.5</td><td>0.2</td></tr><tr><td>
<italic>Ethnicity</italic>
</td><td/><td/><td/><td>0.4</td></tr><tr><td>Caucasian</td><td>14 (78&#x000a0;%)</td><td>14 (78&#x000a0;%)</td><td>15 (88&#x000a0;%)</td><td/></tr><tr><td>Aboriginal or Torres Strait Islander</td><td>0</td><td>1 (6&#x000a0;%)</td><td>0</td><td/></tr><tr><td>Maori/Pacific Islander</td><td>0</td><td>1 (6&#x000a0;%)</td><td>0</td><td/></tr><tr><td>Asian</td><td>3 (17&#x000a0;%)</td><td>2 (11&#x000a0;%)</td><td>0</td><td/></tr><tr><td>Other</td><td>1 (6&#x000a0;%)</td><td>0</td><td>2 (12&#x000a0;%)</td><td/></tr><tr><td>
<italic>Cause of kidney disease</italic>
<sup>b</sup>
</td><td/><td/><td/><td>0.9</td></tr><tr><td>Diabetes</td><td>8 (44&#x000a0;%)</td><td>8 (47&#x000a0;%)</td><td>5 (29&#x000a0;%)</td><td/></tr><tr><td>Glomerulonephritis</td><td>2 (11&#x000a0;%)</td><td>1 (6&#x000a0;%)</td><td>4 (24&#x000a0;%)</td><td/></tr><tr><td>Analgesic nephropathy</td><td>0</td><td>1 (6&#x000a0;%)</td><td>0</td><td/></tr><tr><td>Polycystic kidney disease</td><td>1 (6&#x000a0;%)</td><td>1 (6&#x000a0;%)</td><td>1 (6&#x000a0;%)</td><td/></tr><tr><td>Reflux nephropathy</td><td>1 (6&#x000a0;%)</td><td>1 (6&#x000a0;%)</td><td>1 (6&#x000a0;%)</td><td/></tr><tr><td>Renovascular disease</td><td>0</td><td>1 (6&#x000a0;%)</td><td>1 (6&#x000a0;%)</td><td/></tr><tr><td>Others</td><td>6 (33)</td><td>4 (24&#x000a0;%)</td><td>5 (29&#x000a0;%)</td><td/></tr><tr><td>
<italic>Type of dialysis</italic>
<sup>b</sup>
</td><td/><td/><td/><td>0.4</td></tr><tr><td>Hemodialysis</td><td>17 (94&#x000a0;%)</td><td>16 (94&#x000a0;%)</td><td>17 (100&#x000a0;%)</td><td/></tr><tr><td>Peritoneal dialysis</td><td>1 (6&#x000a0;%)</td><td>0</td><td>0</td><td/></tr><tr><td>Pre-dialysis</td><td>0</td><td>1 (6&#x000a0;%)</td><td>0</td><td/></tr><tr><td>Diabetes mellitus<sup>c</sup>
</td><td>10 (67&#x000a0;%)</td><td>9 (82&#x000a0;%)</td><td>6 (46&#x000a0;%)</td><td>0.2</td></tr><tr><td>Ischemic heart disease<sup>c</sup>
</td><td>7 (47&#x000a0;%)</td><td>4 (36&#x000a0;%)</td><td>7 (54&#x000a0;%)</td><td>0.7</td></tr><tr><td>Congestive heart failure<sup>c</sup>
</td><td>2 (13&#x000a0;%)</td><td>1 (9&#x000a0;%)</td><td>5 (38&#x000a0;%)</td><td>0.1</td></tr><tr><td>Cerebrovascular disease<sup>c</sup>
</td><td>1 (7&#x000a0;%)</td><td>0</td><td>3 (23&#x000a0;%)</td><td>0.2</td></tr><tr><td>Peripheral vascular disease<sup>c</sup>
</td><td>2 (13&#x000a0;%)</td><td>4 (36&#x000a0;%)</td><td>4 (31&#x000a0;%)</td><td>0.4</td></tr><tr><td>
<italic>Smoking status</italic>
<sup>b</sup>
</td><td/><td/><td/><td>0.3</td></tr><tr><td>Never</td><td>9 (50&#x000a0;%)</td><td>5 (29&#x000a0;%)</td><td>9 (53&#x000a0;%)</td><td/></tr><tr><td>Former</td><td>8 (44&#x000a0;%)</td><td>11 (65&#x000a0;%)</td><td>5 (29&#x000a0;%)</td><td/></tr><tr><td>Current</td><td>1 (6&#x000a0;%)</td><td>1 (6&#x000a0;%)</td><td>3 (18&#x000a0;%)</td><td/></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>28.6&#x02009;&#x000b1;&#x02009;4.8</td><td>30.4&#x02009;&#x000b1;&#x02009;7.4</td><td>29.2&#x02009;&#x000b1;&#x02009;7.6</td><td>0.7</td></tr><tr><td>
<italic>Body mass index category</italic>
</td><td/><td/><td/><td>0.3</td></tr><tr><td>Underweight (&#x0003c;18.5&#x000a0;kg/m<sup>2</sup>)</td><td>0</td><td>0</td><td>0</td><td/></tr><tr><td>Healthy weight (18.5 &#x02013; 24.9&#x000a0;kg/m<sup>2</sup>)</td><td>5 (28&#x000a0;%)</td><td>4 (22&#x000a0;%)</td><td>6 (35&#x000a0;%)</td><td/></tr><tr><td>Overweight (25 &#x02013; 29.9&#x000a0;kg/m<sup>2</sup>)</td><td>9 (50&#x000a0;%)</td><td>6 (33&#x000a0;%)</td><td>3 (18&#x000a0;%)</td><td/></tr><tr><td>Obese (&#x0003e;30&#x000a0;kg/m<sup>2</sup>)</td><td>4 (22&#x000a0;%)</td><td>8 (44&#x000a0;%)</td><td>8 (47&#x000a0;%)</td><td/></tr><tr><td>Hematocrit (%)</td><td>34&#x02009;&#x000b1;&#x02009;3</td><td>32&#x02009;&#x000b1;&#x02009;5</td><td>32&#x02009;&#x000b1;&#x02009;3</td><td>0.7</td></tr><tr><td>Mean cellular volume (fL)</td><td>94.4&#x02009;&#x000b1;&#x02009;7.8</td><td>95.3&#x02009;&#x000b1;&#x02009;6.6</td><td>94.3&#x02009;&#x000b1;&#x02009;5.9</td><td>0.9</td></tr><tr><td>Reticulocyte count (10<sup>9</sup>/L)</td><td>57&#x02009;&#x000b1;&#x02009;21</td><td>74&#x02009;&#x000b1;&#x02009;38</td><td>64&#x02009;&#x000b1;&#x02009;31</td><td>0.3</td></tr><tr><td>Total white cell count (x 10<sup>9</sup> per L)</td><td>6.8&#x02009;&#x000b1;&#x02009;2</td><td>6.4&#x02009;&#x000b1;&#x02009;2.1</td><td>6.6&#x02009;&#x000b1;&#x02009;1.5</td><td>0.9</td></tr><tr><td>Platelet count (x 10<sup>9</sup> per L)<sup>d</sup>
</td><td>207 [164, 286]</td><td>188 [167, 207]</td><td>197 [164, 274]</td><td>0.8</td></tr><tr><td>Ferritin (&#x003bc;g/L)<sup>d</sup>
</td><td>413 [241, 958]</td><td>527 [298, 647]</td><td>487 [315, 594]</td><td>0.9</td></tr><tr><td>Transferrin saturation (%)<sup>d</sup>
</td><td>26 [20, 30]</td><td>22 [17, 30]</td><td>23 [22, 29]</td><td>0.6</td></tr><tr><td>Serum bicarbonate (mmol/L)</td><td>23.3&#x02009;&#x000b1;&#x02009;4</td><td>22.6&#x02009;&#x000b1;&#x02009;3</td><td>23.6&#x02009;&#x000b1;&#x02009;3</td><td>0.6</td></tr><tr><td>Albumin (g/L)</td><td>36&#x02009;&#x000b1;&#x02009;4</td><td>35&#x02009;&#x000b1;&#x02009;4</td><td>35&#x02009;&#x000b1;&#x02009;5</td><td>0.7</td></tr><tr><td>Serum alkaline phosphatase (U/L)<sup>d</sup>
</td><td>89 [64, 121]</td><td>99 [76, 134]</td><td>148 [87, 175]</td><td>0.054</td></tr><tr><td>Gamma-glutamyltransferase (U/L)<sup>d</sup>
</td><td>23 [16, 40]</td><td>25 [17, 60]</td><td>32 [21, 57]</td><td>0.4</td></tr><tr><td>Alanine transaminase (U/L)<sup>d</sup>
</td><td>16 [11, 19]</td><td>15 [9, 22]</td><td>10 [8, 19]</td><td>0.2</td></tr><tr><td>Aspartate transaminase (U/L)<sup>d</sup>
</td><td>18 [13, 22]</td><td>17 [12, 23]</td><td>14 [10, 17]</td><td>0.3</td></tr><tr><td>Lactate dehydrogenase (U/L)</td><td>224&#x02009;&#x000b1;&#x02009;57</td><td>224&#x02009;&#x000b1;&#x02009;85</td><td>265&#x02009;&#x000b1;&#x02009;63</td><td>0.2</td></tr><tr><td>Albumin-corrected calcium (mmol/L)</td><td>2.3&#x02009;&#x000b1;&#x02009;0.2</td><td>2.3&#x02009;&#x000b1;&#x02009;0.1</td><td>2.2&#x02009;&#x000b1;&#x02009;0.2</td><td>0.2</td></tr><tr><td>Phosphate (mmol/L)<sup>e</sup>
</td><td>1.7&#x02009;&#x000b1;&#x02009;0.5</td><td>1.7&#x02009;&#x000b1;&#x02009;0.5</td><td>1.7&#x02009;&#x000b1;&#x02009;0.5</td><td>0.9</td></tr><tr><td>Parathyroid hormone (pmol/L)<sup>d,f</sup>
</td><td>17 [9, 35]</td><td>33 [17, 42]</td><td>32 [16, 65]</td><td>0.2</td></tr><tr><td>C-reactive protein (mg/L)</td><td>3 [2, 21]</td><td>12 [4, 28]</td><td>15 [7, 31]</td><td>0.06</td></tr><tr><td>
<italic>Oxidative stress substudy</italic>
</td><td/><td/><td/><td/></tr><tr><td>n</td><td>14</td><td>13</td><td>14</td><td/></tr><tr><td>Total F2-isoprostanes (pg/mL)<sup>d</sup>
</td><td>133 [87, 213]</td><td>143 [128, 200]</td><td>112 [67, 173]</td><td>0.3</td></tr><tr><td>Glutathione peroxidise activity (U/L)</td><td>177 (13)</td><td>181 (10)</td><td>174 (14)</td><td>0.4</td></tr><tr><td>Superoxide dismutase activity (U/mL)<sup>d,f</sup>
</td><td>1.97 [1.41, 2.6]</td><td>2.01 [1.32, 2.44]</td><td>2.22 [1.71, 2.71]</td><td>0.7</td></tr><tr><td>Protein carbonyls (nmol/mg)<sup>d</sup>
</td><td>0.56 [0.46, 0.6]</td><td>0.55 [0.46, 0.74]</td><td>0.55 [0.51, 0.69]</td><td>0.9</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Patients on darbepoetin were converted to an erythropoietin-equivalent dose using a conversion factor of 200:1</p><p>
<sup>b</sup>1 missing data from medium ERI tertile</p><p>
<sup>c</sup>Missing data- 3, 7 and 4 values missing from low, medium and high ERI tertiles, respectively</p><p>
<sup>d</sup>Median [IQR]</p><p>
<sup>e</sup>to convert phosphate level from mmol/L to mg/dL multiply by 3.1</p><p>
<sup>f</sup>to convert parathyroid level from pmol/L to pg/mL multiply by 9.4</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Determinants of ESA resistance index</title><p>Using simple linear regression, there was a weak but statistically significant association between ERI and alkaline phosphatase (R<sup>2</sup>&#x02009;=&#x02009;0.06, <italic>P</italic>&#x02009;=&#x02009;0.03) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). On multinomial logistic regression, the risk of being in the high ERI tertile relative to the low ERI tertile increased with increasing alkaline phosphatase levels (<italic>P</italic>&#x02009;=&#x02009;0.02). No other variables were significantly associated with ERI on univariate analysis (Tables&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Scatterplot showing the association between serum alkaline phosphatase and ESA resistance index</p></caption><graphic xlink:href="40697_2015_66_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Associations between participant characteristics and ERI by simple linear regression</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>R<sup>2</sup>
</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>Women (Reference men)</td><td char="." align="char">&#x02212;0.02</td><td char="." align="char">0.8</td></tr><tr><td>Non-Caucasians (Reference Caucasians)</td><td char="." align="char">&#x02212;0.02</td><td char="." align="char">0.7</td></tr><tr><td>Diabetes mellitus (Reference non-diabetics)</td><td char="." align="char">0.01</td><td char="." align="char">0.2</td></tr><tr><td>Cause of kidney disease</td><td char="." align="char">&#x02212;0.03</td><td char="." align="char">0.6</td></tr><tr><td>Smoking status</td><td char="." align="char">&#x02212;0.02</td><td char="." align="char">0.6</td></tr><tr><td>Body mass index</td><td char="." align="char">0.02</td><td char="." align="char">0.2</td></tr><tr><td>Ischemic heart disease</td><td char="." align="char">&#x02212;0.01</td><td char="." align="char">0.4</td></tr><tr><td>Congestive heart failure</td><td char="." align="char">0.02</td><td char="." align="char">0.2</td></tr><tr><td>Age</td><td char="." align="char">0.01</td><td char="." align="char">0.2</td></tr><tr><td>Reticulocyte count</td><td char="." align="char">&#x02212;0.01</td><td char="." align="char">0.6</td></tr><tr><td>Total white cell count</td><td char="." align="char">&#x02212;0.02</td><td char="." align="char">0.8</td></tr><tr><td>Ferritin<sup>a</sup>
</td><td char="." align="char">&#x02212;0.01</td><td char="." align="char">0.5</td></tr><tr><td>Transferrin saturation<sup>b</sup>
</td><td char="." align="char">&#x02212;0.01</td><td char="." align="char">0.6</td></tr><tr><td>Albumin</td><td char="." align="char">0.001</td><td char="." align="char">0.3</td></tr><tr><td>Alkaline phosphatase<sup>c</sup>
</td><td char="." align="char">0.06</td><td char="." align="char">0.03</td></tr><tr><td>Gamma-glutamyltransferase<sup>b</sup>
</td><td char="." align="char">0.01</td><td char="." align="char">0.2</td></tr><tr><td>Alanine transaminase<sup>c</sup>
</td><td char="." align="char">0.02</td><td char="." align="char">0.1</td></tr><tr><td>Aspartate transaminase<sup>c</sup>
</td><td char="." align="char">0.04</td><td char="." align="char">0.09</td></tr><tr><td>Lactate dehydrogenase<sup>b</sup>
</td><td char="." align="char">0.07</td><td char="." align="char">0.05</td></tr><tr><td>Albumin-corrected calcium</td><td char="." align="char">0.05</td><td char="." align="char">0.06</td></tr><tr><td>Phosphate</td><td char="." align="char">&#x02212;0.02</td><td char="." align="char">0.9</td></tr><tr><td>Parathyroid hormone<sup>a</sup>
</td><td char="." align="char">0.04</td><td char="." align="char">0.09</td></tr><tr><td>C-reactive protein</td><td char="." align="char">0.03</td><td char="." align="char">0.09</td></tr><tr><td>Total F2-isoprostanes<sup>b</sup>
</td><td char="." align="char">&#x02212;0.01</td><td char="." align="char">0.5</td></tr><tr><td>Glutathione peroxidise activity<sup>d</sup>
</td><td char="." align="char">&#x02212;0.004</td><td char="." align="char">0.9</td></tr><tr><td>Superoxide dismutase activity<sup>e</sup>
</td><td char="." align="char">&#x02212;0.01</td><td char="." align="char">0.5</td></tr><tr><td>Protein carbonyls<sup>e</sup>
</td><td char="." align="char">&#x02212;0.03</td><td char="." align="char">0.9</td></tr></tbody></table><table-wrap-foot><p>The following non-normally distributed variables were transformed to normality of distribution:</p><p>
<sup>a</sup>square root</p><p>
<sup>b</sup>log-transformed</p><p>
<sup>c</sup>reciprocal of square root</p><p>
<sup>d</sup>power of 3</p><p>
<sup>e</sup>reciprocal</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Associations between participant characteristics and ERI by univariate multinomial logistic regression</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Coefficient</th><th>95&#x000a0;% confidence intervals</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>Women (Reference men)</td><td>&#x02212;0.83</td><td>&#x02212;2.19 to 0.53</td><td>0.2</td></tr><tr><td>Non-Caucasians (Reference Caucasians)</td><td>0.76</td><td>&#x02212;1.08 to 2.61</td><td>0.4</td></tr><tr><td>Diabetes mellitus (Reference non-diabetics)</td><td>0.85</td><td>&#x02212;0.68 to 2.38</td><td>0.3</td></tr><tr><td>
<italic>Cause of kidney disease</italic>
</td><td/><td/><td/></tr><tr><td>Diabetes</td><td>Reference</td><td/><td/></tr><tr><td>Glomerulonephritis</td><td>&#x02212;1.16</td><td>&#x02212;3.19 to 0.87</td><td>0.3</td></tr><tr><td>Analgesic nephropathy</td><td>NR</td><td>NR</td><td>NR</td></tr><tr><td>Polycystic kidney disease</td><td>&#x02212;0.47</td><td>&#x02212;3.46 to 2.52</td><td>0.8</td></tr><tr><td>Reflux nephropathy</td><td>&#x02212;0.47</td><td>&#x02212;3.46 to 2.52</td><td>0.8</td></tr><tr><td>Renovascular disease</td><td>NR</td><td>NR</td><td>NR</td></tr><tr><td>Others</td><td>&#x02212;0.29</td><td>&#x02212;1.92 to 1.34</td><td>0.7</td></tr><tr><td>
<italic>Smoking status</italic>
</td><td/><td/><td/></tr><tr><td>Never</td><td>Reference</td><td/><td/></tr><tr><td>Former</td><td>0.47</td><td>&#x02212;0.98 to 1.92</td><td>0.5</td></tr><tr><td>Current</td><td>&#x02212;1.10</td><td>&#x02212;3.54 to 1.35</td><td>0.4</td></tr><tr><td>
<italic>Body mass index category</italic>
</td><td/><td/><td/></tr><tr><td>Healthy weight</td><td>Reference</td><td/><td/></tr><tr><td>Overweight</td><td>1.28</td><td>&#x02212;0.48 to 3.05</td><td>0.2</td></tr><tr><td>Obese</td><td>&#x02212;0.51</td><td>&#x02212;2.20 to 1.18</td><td>0.6</td></tr><tr><td>Ischemic heart disease</td><td>&#x02212;0.28</td><td>&#x02212;1.78 to 1.20</td><td>0.7</td></tr><tr><td>Congestive heart failure</td><td>&#x02212;1.40</td><td>&#x02212;3.26 to 0.46</td><td>0.1</td></tr><tr><td>Age</td><td>0.03</td><td>&#x02212;0.01 to 0.08</td><td>0.2</td></tr><tr><td>Reticulocyte count</td><td>&#x02212;0.01</td><td>&#x02212;0.03 to 0.02</td><td>0.5</td></tr><tr><td>Total white cell count</td><td>0.03</td><td>&#x02212;0.33 to 0.40</td><td>0.9</td></tr><tr><td>Ferritin<sup>a</sup>
</td><td>0.01</td><td>&#x02212;0.09 to 0.11</td><td>0.8</td></tr><tr><td>Transferrin saturation<sup>b</sup>
</td><td>0.05</td><td>&#x02212;2.29 to 2.39</td><td>0.9</td></tr><tr><td>Albumin</td><td>0.06</td><td>&#x02212;0.09 to 0.21</td><td>0.4</td></tr><tr><td>Alkaline phosphatase<sup>c</sup>
</td><td>44.01</td><td>7.63 to 80.40</td><td>0.02</td></tr><tr><td>Gamma-glutamyltransferase<sup>b</sup>
</td><td>&#x02212;0.65</td><td>&#x02212;1.60 to 0.30</td><td>0.2</td></tr><tr><td>Alanine transaminase<sup>c</sup>
</td><td>&#x02212;7.42</td><td>&#x02212;16.80 to 1.96</td><td>0.1</td></tr><tr><td>Aspartate transaminase<sup>c</sup>
</td><td>&#x02212;8.50</td><td>&#x02212;20.62 to 3.62</td><td>0.2</td></tr><tr><td>Lactate dehydrogenase<sup>b</sup>
</td><td>&#x02212;2.18</td><td>&#x02212;5.06 to 0.69</td><td>0.1</td></tr><tr><td>Albumin-corrected calcium</td><td>3.46</td><td>&#x02212;0.60 to 7.51</td><td>0.09</td></tr><tr><td>Phosphate</td><td>&#x02212;0.01</td><td>&#x02212;1.31 to 1.29</td><td>0.9</td></tr><tr><td>Parathyroid hormone<sup>a</sup>
</td><td>&#x02212;0.25</td><td>&#x02212;0.55 to 0.05</td><td>0.1</td></tr><tr><td>C-reactive protein</td><td>&#x02212;0.03</td><td>&#x02212;0.08 to 0.01</td><td>0.2</td></tr><tr><td>Total F2-isoprostanes<sup>b</sup>
</td><td>0.36</td><td>&#x02212;0.69 to 1.42</td><td>0.5</td></tr><tr><td>Glutathione peroxidise activity<sup>d</sup>
</td><td>NR</td><td>NR</td><td>NR</td></tr><tr><td>Superoxide dismutase activity<sup>e</sup>
</td><td>1.49</td><td>&#x02212;1.91 to 4.90</td><td>0.4</td></tr><tr><td>Protein carbonyls<sup>e</sup>
</td><td>0.24</td><td>&#x02212;1.26 to 1.74</td><td>0.8</td></tr></tbody></table><table-wrap-foot><p>
<italic>NR</italic> Estimates could not be obtained due to small number of patients</p><p>The following non-normally distributed variables were transformed to normality of distribution:</p><p>
<sup>a</sup>square root</p><p>
<sup>b</sup>log-transformed</p><p>
<sup>c</sup>reciprocal of square root</p><p>
<sup>d</sup>power of 3</p><p>
<sup>e</sup> reciprocal</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec10" sec-type="discussion"><title>Discussion</title><p>This secondary analysis of the HERO Study showed that serum alkaline phosphatase was associated with severity of ESA resistance in a selected group of patients with advanced CKD who did not have any identifiable cause of ESA-resistant anemia. No other factors were found to be associated with severity of ESA resistance.</p><p>In a study involving 38,328 ESKD patients receiving hemodialysis, Kalantar-Zadeh and colleagues reported a positive association between serum alkaline phosphatase level and ESA hyporesponsiveness [<xref ref-type="bibr" rid="CR15">15</xref>]. Importantly, this association persisted even after adjusting for other known causes of anemia, such as older age, gender, diabetes mellitus, body mass index, iron studies, markers of bone disease, parathyroid level and markers of malnutrition. Other investigators have reported improvement in hemoglobin concentration and reductions in the serum alkaline phosphatase level and ESA dose after parathyroidectomy [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Previous studies have also demonstrated that alkaline phosphatase is associated with mortality in ESKD patients receiving dialysis [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>] and pre-dialysis patients with CKD [<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR43">43</xref>]. A major difference between the present study and previous investigations is that the HERO study excluded patients with any identifiable cause of ESA-resistant anemia, such as deficiencies of iron or vitamin B12 or folate, bleeding, inadequate dialysis, severe hyperparathyroidism (PTH &#x0003e;100 pmol/L), malignancy or hematologic disorder, major surgery, infection, acute myocardial infarction or malignancy within the last 3&#x000a0;months. Indeed, this is the first study describing the determinants of severity of ESA resistance in patients with primary ESA-resistance, as previous studies included patients with no ESA resistance as well as those with known secondary causes of ESA resistance.</p><p>Approximately 31&#x02013;37&#x000a0;% of ESKD patients receiving dialysis have raised levels of serum alkaline phosphatase [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Serum alkaline phosphatase in the dialysis population is strongly associated with serum concentrations of parathyroid hormone and aspartate transaminase [<xref ref-type="bibr" rid="CR36">36</xref>]. Although bone and liver alkaline phosphatase are found in equal proportions in healthy adults, 28&#x000a0;% of ESKD patients on haemodialysis with increased bone alkaline phosphatase have normal alkaline phosphatase levels [<xref ref-type="bibr" rid="CR44">44</xref>]. In a study involving 800 ESKD patients receiving haemodialysis, Drechsler and colleagues showed a strong association between bone alkaline phosphatase and all-cause and cardiovascular mortality [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p>The most likely reason for the observed association between alkaline phosphatase and severity of ESA resistance in the present study is increased bone turnover and marrow fibrosis, since the median serum PTH levels in the middle and high ERI tertiles were 33 and 32 pmol/L, respectively compared with 17 pmol/L in the low ERI tertile [<xref ref-type="bibr" rid="CR45">45</xref>]. In the current study, there was no statistically significant association observed between parathyroid hormone and primary ESA-resistance. It is important to note that the HERO Study excluded patients with a serum parathyroid hormone level greater than 100 pmol/L, such that included patients only had mild-to-moderate secondary hyperparathyroidism. Nevertheless, even at these relatively modest elevations of serum PTH, alkaline phosphatase was still significantly associated with ESA resistance.</p><p>A strength of the study was that it involved patients from multiple centers across two countries, enhancing the internal and external validity of the findings. On the other hand, the study was limited by a relatively small sample size, such that it is possible that some associations with severity of ESA resistance were not able to be ascertained due to a type 2 statistical error. Moreover, as multiple variables were evaluated in this study, the observed association between alkaline phosphatase and severity of ESA resistance could have been due to a type 1 statistical error. Bone-specific alkaline phosphatase, other markers of bone turnover and bone biopsies were not evaluated, thereby limiting more detailed exploration of the potential mechanisms underpinning the association between serum alkaline phosphatase and severity of ESA resistance. Since the HERO study included a highly selected group of patients with no identifiable cause of ESA-resistant anemia, the findings of this study may not be generalizable to patients with a known cause of ESA hyporesponsiveness. This finding is hypothesis generating and needs to be confirmed by other studies.</p></sec><sec id="Sec11" sec-type="conclusion"><title>Conclusions</title><p>Alkaline phosphatase was associated with severity of ESA resistance in patients with advanced CKD and no apparent secondary cause of ESA-resistance. Larger prospective studies are required to confirm this association.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACE</term><def><p>Angiotensin converting enzyme</p></def></def-item><def-item><term>CKD</term><def><p>Chronic kidney disease</p></def></def-item><def-item><term>ERI</term><def><p>Erythropoiesis resistance index</p></def></def-item><def-item><term>ESA</term><def><p>Erythropoiesis stimulating agents</p></def></def-item><def-item><term>ESKD</term><def><p>End-stage kidney disease</p></def></def-item><def-item><term>GPX</term><def><p>Glutathione peroxidase</p></def></def-item><def-item><term>HERO</term><def><p>The Handling Erythropoietin Resistance with Oxpentifylline trial</p></def></def-item><def-item><term>IQR</term><def><p>Interquartile range</p></def></def-item><def-item><term>PTH</term><def><p>Parathyroid hormone</p></def></def-item><def-item><term>SOD</term><def><p>Superoxide dismutase</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>DWJ has previously received consultancy fees from Sanofi-Aventis. He has also previously received consultancy fees, speakers&#x02019; honoraria, research grants and travel sponsorships from Amgen, Roche and Janssen-Cilag. He was the recipient of a Roche Foundation for Anemia Research (RoFAR) Grant, which partly funded the HERO trial, and a Queensland Government Health Research Fellowship. CMH has previously received consultancy fees, speakers&#x02019; honoraria, research grants and/or travel sponsorships from Amgen, Roche and Janssen-Cilag. JC has received a speakers&#x02019; honorarium from Roche. AC has previously received consultancy fees, speakers&#x02019; honoraria and/or research grants from Amgen, Roche, Baxter, Fresenius and Merck. RW has previously received consultancy fees, speakers&#x02019; honoraria, research grants and travel sponsorships from Amgen, Roche and Janssen-Cilag and has served on Advisory Boards for Amgen, Roche and Janssen-Cilag. EP has previously received consultancy fees, speakers&#x02019; honoraria, research grants and/or travel sponsorships from Amgen, Sanofi and Roche. All other authors have no conflict of interest to declare.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>DWJ, CMH, JSC, AC, PC, PF, SPM, EP, VP, SB and RW conceived the study design. ATM, DR and LAV contributed acquisition of data. SB, LZ, EMP and AS contributed to data analysis. SB, LZ and DWJ drafted the manuscript. All authors contributed to interpretation of results and critical review of the manuscript. All authors read and approved the final manuscript. All authors are in agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The HERO Study Collaborative Group comprises the Trial Management Committee (Emmanuel d&#x02019;Almeida (Department of Nephrology, John Hunter Hospital, Newcastle, Australia), Rob Fassett (Department of Nephrology, Royal Brisbane and Women&#x02019;s Hospital, Brisbane, Australia), Carl Kirkpatrick (Center for Medicine Use and Safety, Monash University, Melbourne, Australia), Richard Phoon (Department of Nephrology, Westmead Hospital, Sydney, Australia), and the members of the Writing Committee.</p><sec id="FPar1"><title>Financial support</title><p>The HERO trial was funded by research grants from Roche Foundation for Anemia Research (RoFAR), Amgen, Janssen-Cilag and the National Health and Medical Research Council of Australia. The funders had no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eschbach</surname><given-names>JW</given-names></name><name><surname>Egrie</surname><given-names>JC</given-names></name><name><surname>Downing</surname><given-names>MR</given-names></name><name><surname>Browne</surname><given-names>JK</given-names></name><name><surname>Adamson</surname><given-names>JW</given-names></name></person-group><article-title>Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial</article-title><source>N Engl J Med</source><year>1987</year><volume>316</volume><issue>2</issue><fpage>73</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1056/NEJM198701083160203</pub-id><pub-id pub-id-type="pmid">3537801</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messana</surname><given-names>JM</given-names></name><name><surname>Chuang</surname><given-names>CC</given-names></name><name><surname>Turenne</surname><given-names>M</given-names></name><name><surname>Wheeler</surname><given-names>J</given-names></name><name><surname>Turner</surname><given-names>J</given-names></name><name><surname>Sleeman</surname><given-names>K</given-names></name><etal/></person-group><article-title>Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model</article-title><source>Am J Kidney Dis</source><year>2009</year><volume>53</volume><issue>3</issue><fpage>503</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2008.10.047</pub-id><pub-id pub-id-type="pmid">19185402</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ofsthun</surname><given-names>N</given-names></name><name><surname>Labrecque</surname><given-names>J</given-names></name><name><surname>Lacson</surname><given-names>E</given-names></name><name><surname>Keen</surname><given-names>M</given-names></name><name><surname>Lazarus</surname><given-names>JM</given-names></name></person-group><article-title>The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients</article-title><source>Kidney Int</source><year>2003</year><volume>63</volume><issue>5</issue><fpage>1908</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00937.x</pub-id><pub-id pub-id-type="pmid">12675871</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdougall</surname><given-names>IC</given-names></name><name><surname>Tomson</surname><given-names>CR</given-names></name><name><surname>Steenkamp</surname><given-names>M</given-names></name><name><surname>Ansell</surname><given-names>D</given-names></name></person-group><article-title>Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: an observational study using UK Renal Registry data incorporating 30,040 patient-years of follow-up</article-title><source>Nephrol Dial Transplant</source><year>2010</year><volume>25</volume><issue>3</issue><fpage>914</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfp550</pub-id><pub-id pub-id-type="pmid">19934090</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lurdes Agostinho Cabrita</surname><given-names>A</given-names></name><name><surname>Pinho</surname><given-names>A</given-names></name><name><surname>Malho</surname><given-names>A</given-names></name><name><surname>Morgado</surname><given-names>E</given-names></name><name><surname>Faisca</surname><given-names>M</given-names></name><name><surname>Carrasqueira</surname><given-names>H</given-names></name><etal/></person-group><article-title>Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5</article-title><source>Int Urol Nephrol</source><year>2011</year><volume>43</volume><issue>3</issue><fpage>835</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1007/s11255-010-9805-9</pub-id><pub-id pub-id-type="pmid">20640598</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Iorio</surname><given-names>BR</given-names></name><name><surname>Stellato</surname><given-names>D</given-names></name><name><surname>De Santo</surname><given-names>NG</given-names></name><name><surname>Cirillo</surname><given-names>M</given-names></name></person-group><article-title>Association of gender and age with erythropoietin resistance in hemodialysis patients: role of menstrual status</article-title><source>Blood Purif</source><year>2004</year><volume>22</volume><issue>5</issue><fpage>423</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1159/000080234</pub-id><pub-id pub-id-type="pmid">15316197</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Gomez</surname><given-names>JM</given-names></name><name><surname>Portoles</surname><given-names>JM</given-names></name><name><surname>Aljama</surname><given-names>P</given-names></name></person-group><article-title>Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality</article-title><source>Kidney Int Suppl</source><year>2008</year><volume>111</volume><fpage>S75</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1038/ki.2008.523</pub-id><pub-id pub-id-type="pmid">19034333</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallick</surname><given-names>S</given-names></name><name><surname>Rafiroiu</surname><given-names>A</given-names></name><name><surname>Kanthety</surname><given-names>R</given-names></name><name><surname>Iqbal</surname><given-names>S</given-names></name><name><surname>Malik</surname><given-names>R</given-names></name><name><surname>Rahman</surname><given-names>M</given-names></name></person-group><article-title>Factors predicting erythropoietin resistance among maintenance hemodialysis patients</article-title><source>Blood Purif</source><year>2012</year><volume>33</volume><issue>4</issue><fpage>238</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1159/000335256</pub-id><pub-id pub-id-type="pmid">22378310</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Okada</surname><given-names>K</given-names></name><name><surname>Maruyama</surname><given-names>T</given-names></name><name><surname>Maruyama</surname><given-names>N</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Soma</surname><given-names>M</given-names></name></person-group><article-title>Relationship between erythropoietin responsiveness, insulin resistance, and malnutrition-inflammation-atherosclerosis (MIA) syndrome in hemodialysis patients with diabetes</article-title><source>Int J Artif Organs</source><year>2011</year><volume>34</volume><issue>1</issue><fpage>16</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.5301/IJAO.2011.6314</pub-id><pub-id pub-id-type="pmid">21298620</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Andrulli</surname><given-names>S</given-names></name><name><surname>Memoli</surname><given-names>B</given-names></name><name><surname>Maffei</surname><given-names>C</given-names></name><name><surname>Del Vecchio</surname><given-names>L</given-names></name><name><surname>Aterini</surname><given-names>S</given-names></name><etal/></person-group><article-title>Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients</article-title><source>Nephrol Dial Transplant</source><year>2006</year><volume>21</volume><issue>4</issue><fpage>991</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfk011</pub-id><pub-id pub-id-type="pmid">16384825</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunnell</surname><given-names>J</given-names></name><name><surname>Yeun</surname><given-names>JY</given-names></name><name><surname>Depner</surname><given-names>TA</given-names></name><name><surname>Kaysen</surname><given-names>GA</given-names></name></person-group><article-title>Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients</article-title><source>Am J Kidney Dis</source><year>1999</year><volume>33</volume><issue>1</issue><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/S0272-6386(99)70259-3</pub-id><pub-id pub-id-type="pmid">9915269</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>E</given-names></name><name><surname>Lima</surname><given-names>M</given-names></name><name><surname>Alves</surname><given-names>JM</given-names></name><name><surname>Rocha</surname><given-names>S</given-names></name><name><surname>Rocha-Pereira</surname><given-names>P</given-names></name><name><surname>Castro</surname><given-names>E</given-names></name><etal/></person-group><article-title>Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy</article-title><source>J Clin Immunol</source><year>2008</year><volume>28</volume><issue>3</issue><fpage>268</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1007/s10875-007-9168-x</pub-id><pub-id pub-id-type="pmid">18205031</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pajek</surname><given-names>J</given-names></name><name><surname>Bucar-Pajek</surname><given-names>M</given-names></name><name><surname>Grego</surname><given-names>K</given-names></name><name><surname>Gucek</surname><given-names>A</given-names></name><name><surname>Bevc</surname><given-names>S</given-names></name><name><surname>Ekart</surname><given-names>R</given-names></name><etal/></person-group><article-title>Epoetin responsiveness in peritoneal dialysis patients: a multi-center Slovenian study</article-title><source>Ther Apher Dial</source><year>2005</year><volume>9</volume><issue>3</issue><fpage>228</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/j.1774-9987.2005.00260.x</pub-id><pub-id pub-id-type="pmid">15966995</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szczech</surname><given-names>LA</given-names></name><name><surname>Barnhart</surname><given-names>HX</given-names></name><name><surname>Inrig</surname><given-names>JK</given-names></name><name><surname>Reddan</surname><given-names>DN</given-names></name><name><surname>Sapp</surname><given-names>S</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes</article-title><source>Kidney Int</source><year>2008</year><volume>74</volume><issue>6</issue><fpage>791</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/ki.2008.295</pub-id><pub-id pub-id-type="pmid">18596733</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalantar-Zadeh</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>GH</given-names></name><name><surname>Miller</surname><given-names>JE</given-names></name><name><surname>Streja</surname><given-names>E</given-names></name><name><surname>Jing</surname><given-names>J</given-names></name><name><surname>Robertson</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients</article-title><source>Am J Kidney Dis</source><year>2009</year><volume>53</volume><issue>5</issue><fpage>823</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2008.12.040</pub-id><pub-id pub-id-type="pmid">19339087</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zachee</surname><given-names>P</given-names></name><name><surname>Chew</surname><given-names>SL</given-names></name><name><surname>Daelemans</surname><given-names>R</given-names></name><name><surname>Lins</surname><given-names>RL</given-names></name></person-group><article-title>Erythropoietin resistance due to vitamin B12 deficiency. Case report and retrospective analysis of B12 levels after erythropoietin treatment</article-title><source>Am J Nephrol</source><year>1992</year><volume>12</volume><issue>3</issue><fpage>188</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1159/000168443</pub-id><pub-id pub-id-type="pmid">1415379</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bamgbola</surname><given-names>OF</given-names></name><name><surname>Kaskel</surname><given-names>F</given-names></name></person-group><article-title>Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis</article-title><source>Pediatr Nephrol</source><year>2005</year><volume>20</volume><issue>11</issue><fpage>1622</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s00467-005-2021-7</pub-id><pub-id pub-id-type="pmid">16133045</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiss</surname><given-names>Z</given-names></name><name><surname>Ambrus</surname><given-names>C</given-names></name><name><surname>Almasi</surname><given-names>C</given-names></name><name><surname>Berta</surname><given-names>K</given-names></name><name><surname>Deak</surname><given-names>G</given-names></name><name><surname>Horonyi</surname><given-names>P</given-names></name><etal/></person-group><article-title>Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis</article-title><source>Nephron Clin Pract</source><year>2011</year><volume>117</volume><issue>4</issue><fpage>c373</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1159/000321521</pub-id><pub-id pub-id-type="pmid">21071961</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diskin</surname><given-names>CJ</given-names></name><name><surname>Stokes</surname><given-names>TJ</given-names></name><name><surname>Dansby</surname><given-names>LM</given-names></name><name><surname>Radcliff</surname><given-names>L</given-names></name><name><surname>Carter</surname><given-names>TB</given-names></name></person-group><article-title>Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients?</article-title><source>Nephrology (Carlton)</source><year>2006</year><volume>11</volume><issue>5</issue><fpage>394</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1797.2006.00674.x</pub-id><pub-id pub-id-type="pmid">17014551</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muirhead</surname><given-names>N</given-names></name><name><surname>Hodsman</surname><given-names>AB</given-names></name></person-group><article-title>Occult infection and resistance of anaemia to rHuEpo therapy in renal failure</article-title><source>Nephrol Dial Transplant</source><year>1990</year><volume>5</volume><issue>3</issue><fpage>232</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1093/ndt/5.3.232</pub-id><pub-id pub-id-type="pmid">2113653</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nassar</surname><given-names>GM</given-names></name><name><surname>Fishbane</surname><given-names>S</given-names></name><name><surname>Ayus</surname><given-names>JC</given-names></name></person-group><article-title>Occult infection of old nonfunctioning arteriovenous grafts: a novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients</article-title><source>Kidney Int Suppl</source><year>2002</year><volume>80</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.61.s80.10.x</pub-id><pub-id pub-id-type="pmid">11982813</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeLong</surname><given-names>M</given-names></name><name><surname>Logan</surname><given-names>JL</given-names></name><name><surname>Yong</surname><given-names>KC</given-names></name><name><surname>Lien</surname><given-names>YH</given-names></name></person-group><article-title>Renin-angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance</article-title><source>Nephrol Dial Transplant</source><year>2005</year><volume>20</volume><issue>3</issue><fpage>585</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfh638</pub-id><pub-id pub-id-type="pmid">15735242</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Gomez</surname><given-names>JM</given-names></name><name><surname>Perez-Flores</surname><given-names>I</given-names></name><name><surname>Jofre</surname><given-names>R</given-names></name><name><surname>Carretero</surname><given-names>D</given-names></name><name><surname>Rodriguez-Benitez</surname><given-names>P</given-names></name><name><surname>Villaverde</surname><given-names>M</given-names></name><etal/></person-group><article-title>Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance</article-title><source>J Am Soc Nephrol</source><year>2004</year><volume>15</volume><issue>9</issue><fpage>2494</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1097/01.ASN.0000137879.97445.6E</pub-id><pub-id pub-id-type="pmid">15340000</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casadevall</surname><given-names>N</given-names></name><name><surname>Nataf</surname><given-names>J</given-names></name><name><surname>Viron</surname><given-names>B</given-names></name><name><surname>Kolta</surname><given-names>A</given-names></name><name><surname>Kiladjian</surname><given-names>JJ</given-names></name><name><surname>Martin-Dupont</surname><given-names>P</given-names></name><etal/></person-group><article-title>Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><issue>7</issue><fpage>469</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa011931</pub-id><pub-id pub-id-type="pmid">11844847</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phrommintikul</surname><given-names>A</given-names></name><name><surname>Haas</surname><given-names>SJ</given-names></name><name><surname>Elsik</surname><given-names>M</given-names></name><name><surname>Krum</surname><given-names>H</given-names></name></person-group><article-title>Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis</article-title><source>Lancet</source><year>2007</year><volume>369</volume><issue>9559</issue><fpage>381</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)60194-9</pub-id><pub-id pub-id-type="pmid">17276778</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>SC</given-names></name><name><surname>Navaneethan</surname><given-names>SD</given-names></name><name><surname>Craig</surname><given-names>JC</given-names></name><name><surname>Johnson</surname><given-names>DW</given-names></name><name><surname>Tonelli</surname><given-names>M</given-names></name><name><surname>Garg</surname><given-names>AX</given-names></name><etal/></person-group><article-title>Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease</article-title><source>Ann Intern Med</source><year>2010</year><volume>153</volume><issue>1</issue><fpage>23</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-153-1-201007060-00252</pub-id><pub-id pub-id-type="pmid">20439566</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilpatrick</surname><given-names>RD</given-names></name><name><surname>Critchlow</surname><given-names>CW</given-names></name><name><surname>Fishbane</surname><given-names>S</given-names></name><name><surname>Besarab</surname><given-names>A</given-names></name><name><surname>Stehman-Breen</surname><given-names>C</given-names></name><name><surname>Krishnan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients</article-title><source>Clin J Am Soc Nephrol</source><year>2008</year><volume>3</volume><issue>4</issue><fpage>1077</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.2215/CJN.04601007</pub-id><pub-id pub-id-type="pmid">18417744</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regidor</surname><given-names>DL</given-names></name><name><surname>Kopple</surname><given-names>JD</given-names></name><name><surname>Kovesdy</surname><given-names>CP</given-names></name><name><surname>Kilpatrick</surname><given-names>RD</given-names></name><name><surname>McAllister</surname><given-names>CJ</given-names></name><name><surname>Aronovitz</surname><given-names>J</given-names></name><etal/></person-group><article-title>Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients</article-title><source>J Am Soc Nephrol</source><year>2006</year><volume>17</volume><issue>4</issue><fpage>1181</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1681/ASN.2005090997</pub-id><pub-id pub-id-type="pmid">16565261</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Uno</surname><given-names>H</given-names></name><name><surname>Lewis</surname><given-names>EF</given-names></name><name><surname>Eckardt</surname><given-names>K-U</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Burdmann</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>12</issue><fpage>1146</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1005109</pub-id><pub-id pub-id-type="pmid">20843249</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badve</surname><given-names>SV</given-names></name><name><surname>Hawley</surname><given-names>CM</given-names></name><name><surname>Johnson</surname><given-names>DW</given-names></name></person-group><article-title>Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD?</article-title><source>Nephrology (Carlton)</source><year>2011</year><volume>16</volume><issue>2</issue><fpage>144</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1797.2010.01407.x</pub-id><pub-id pub-id-type="pmid">21272125</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badve</surname><given-names>SV</given-names></name><name><surname>Beller</surname><given-names>EM</given-names></name><name><surname>Cass</surname><given-names>A</given-names></name><name><surname>Francis</surname><given-names>DP</given-names></name><name><surname>Hawley</surname><given-names>C</given-names></name><name><surname>Macdougall</surname><given-names>IC</given-names></name><etal/></person-group><article-title>Interventions for erythropoietin-resistant anaemia in dialysis patients</article-title><source>Cochrane Database Syst Rev</source><year>2013</year><volume>8</volume><pub-id pub-id-type="pmid">23979995</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>DW</given-names></name><name><surname>Pascoe</surname><given-names>EM</given-names></name><name><surname>Badve</surname><given-names>SV</given-names></name><name><surname>Dalziel</surname><given-names>K</given-names></name><name><surname>Cass</surname><given-names>A</given-names></name><name><surname>Clarke</surname><given-names>P</given-names></name><etal/></person-group><article-title>A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial</article-title><source>Am J Kidney Dis</source><year>2015</year><volume>65</volume><issue>1</issue><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2014.06.020</pub-id><pub-id pub-id-type="pmid">25115616</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>DW</given-names></name><name><surname>Hawley</surname><given-names>CM</given-names></name><name><surname>Rosser</surname><given-names>B</given-names></name><name><surname>Beller</surname><given-names>E</given-names></name><name><surname>Thompson</surname><given-names>C</given-names></name><name><surname>Fassett</surname><given-names>RG</given-names></name><etal/></person-group><article-title>Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial</article-title><source>BMC Nephrol</source><year>2008</year><volume>9</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/1471-2369-9-8</pub-id><pub-id pub-id-type="pmid">18671885</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>TL</given-names></name><name><surname>Chan</surname><given-names>TT</given-names></name><name><surname>Ho</surname><given-names>YW</given-names></name><name><surname>Lam</surname><given-names>SH</given-names></name></person-group><article-title>Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis</article-title><source>Arch Surg</source><year>2007</year><volume>142</volume><issue>7</issue><fpage>644</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1001/archsurg.142.7.644</pub-id><pub-id pub-id-type="pmid">17638802</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trunzo</surname><given-names>JA</given-names></name><name><surname>McHenry</surname><given-names>CR</given-names></name><name><surname>Schulak</surname><given-names>JA</given-names></name><name><surname>Wilhelm</surname><given-names>SM</given-names></name></person-group><article-title>Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism</article-title><source>Surgery</source><year>2008</year><volume>144</volume><issue>6</issue><fpage>915</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.surg.2008.07.026</pub-id><pub-id pub-id-type="pmid">19040997</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regidor</surname><given-names>DL</given-names></name><name><surname>Kovesdy</surname><given-names>CP</given-names></name><name><surname>Mehrotra</surname><given-names>R</given-names></name><name><surname>Rambod</surname><given-names>M</given-names></name><name><surname>Jing</surname><given-names>J</given-names></name><name><surname>McAllister</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients</article-title><source>J Am Soc Nephrol</source><year>2008</year><volume>19</volume><issue>11</issue><fpage>2193</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1681/ASN.2008010014</pub-id><pub-id pub-id-type="pmid">18667733</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drechsler</surname><given-names>C</given-names></name><name><surname>Verduijn</surname><given-names>M</given-names></name><name><surname>Pilz</surname><given-names>S</given-names></name><name><surname>Krediet</surname><given-names>RT</given-names></name><name><surname>Dekker</surname><given-names>FW</given-names></name><name><surname>Wanner</surname><given-names>C</given-names></name><etal/></person-group><article-title>Bone alkaline phosphatase and mortality in dialysis patients</article-title><source>Clin J Am Soc Nephrol</source><year>2011</year><volume>6</volume><issue>7</issue><fpage>1752</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.2215/CJN.10091110</pub-id><pub-id pub-id-type="pmid">21597029</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nigwekar</surname><given-names>SU</given-names></name><name><surname>Wenger</surname><given-names>J</given-names></name><name><surname>Thadhani</surname><given-names>R</given-names></name><name><surname>Bhan</surname><given-names>I</given-names></name></person-group><article-title>Hyponatremia, mineral metabolism, and mortality in incident maintenance hemodialysis patients: a cohort study</article-title><source>Am J Kidney Dis</source><year>2013</year><volume>62</volume><issue>4</issue><fpage>755</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2013.02.367</pub-id><pub-id pub-id-type="pmid">23591291</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>CM</given-names></name><name><surname>Molnar</surname><given-names>MZ</given-names></name><name><surname>Lau</surname><given-names>WL</given-names></name><name><surname>Ravel</surname><given-names>V</given-names></name><name><surname>Kovesdy</surname><given-names>CP</given-names></name><name><surname>Mehrotra</surname><given-names>R</given-names></name><etal/></person-group><article-title>Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis</article-title><source>Perit Dial Int</source><year>2014</year><volume>34</volume><issue>7</issue><fpage>732</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.3747/pdi.2013.00110</pub-id><pub-id pub-id-type="pmid">24385335</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beddhu</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Baird</surname><given-names>B</given-names></name><name><surname>Cheung</surname><given-names>AK</given-names></name><name><surname>Greene</surname><given-names>T</given-names></name></person-group><article-title>Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease</article-title><source>Clin J Am Soc Nephrol</source><year>2009</year><volume>4</volume><issue>11</issue><fpage>1805</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.2215/CJN.01560309</pub-id><pub-id pub-id-type="pmid">19729429</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovesdy</surname><given-names>CP</given-names></name><name><surname>Ureche</surname><given-names>V</given-names></name><name><surname>Lu</surname><given-names>JL</given-names></name><name><surname>Kalantar-Zadeh</surname><given-names>K</given-names></name></person-group><article-title>Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD</article-title><source>Nephrol Dial Transplant</source><year>2010</year><volume>25</volume><issue>9</issue><fpage>3003</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfq144</pub-id><pub-id pub-id-type="pmid">20299338</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taliercio</surname><given-names>JJ</given-names></name><name><surname>Schold</surname><given-names>JD</given-names></name><name><surname>Simon</surname><given-names>JF</given-names></name><name><surname>Arrigain</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>A</given-names></name><name><surname>Saab</surname><given-names>G</given-names></name><etal/></person-group><article-title>Prognostic importance of serum alkaline phosphatase in CKD stages 3&#x02013;4 in a clinical population</article-title><source>Am J Kidney Dis</source><year>2013</year><volume>62</volume><issue>4</issue><fpage>703</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2013.04.012</pub-id><pub-id pub-id-type="pmid">23769134</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beige</surname><given-names>J</given-names></name><name><surname>Wendt</surname><given-names>R</given-names></name><name><surname>Girndt</surname><given-names>M</given-names></name><name><surname>Queck</surname><given-names>KH</given-names></name><name><surname>Fiedler</surname><given-names>R</given-names></name><name><surname>Jehle</surname><given-names>P</given-names></name></person-group><article-title>Association of serum alkaline phosphatase with mortality in non-selected European patients with CKD5D: an observational, three-centre survival analysis</article-title><source>BMJ Open</source><year>2014</year><volume>4</volume><issue>2</issue><pub-id pub-id-type="doi">10.1136/bmjopen-2013-004275</pub-id><pub-id pub-id-type="pmid">24578540</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tibi</surname><given-names>L</given-names></name><name><surname>Chhabra</surname><given-names>SC</given-names></name><name><surname>Sweeting</surname><given-names>VM</given-names></name><name><surname>Winney</surname><given-names>RJ</given-names></name><name><surname>Smith</surname><given-names>AF</given-names></name></person-group><article-title>Multiple forms of alkaline phosphatase in plasma of hemodialysis patients</article-title><source>Clin Chem</source><year>1991</year><volume>37</volume><issue>6</issue><fpage>815</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">1675597</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barreto</surname><given-names>FC</given-names></name><name><surname>Barreto</surname><given-names>DV</given-names></name><name><surname>Moyses</surname><given-names>RM</given-names></name><name><surname>Neves</surname><given-names>KR</given-names></name><name><surname>Canziani</surname><given-names>ME</given-names></name><name><surname>Draibe</surname><given-names>SA</given-names></name><etal/></person-group><article-title>K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients</article-title><source>Kidney Int</source><year>2008</year><volume>73</volume><issue>6</issue><fpage>771</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5002769</pub-id><pub-id pub-id-type="pmid">18185506</pub-id></element-citation></ref></ref-list></back></article>